When the EGFR kinase activity is targeted by therapeutic drugs, the oral squamous cell carcinoma cells lose proliferative ability, making these reagents effective in targeting oral squamous cell carcinoma cells [27,28]. This evidence concerns the gene EGFR and oral cavity squamous cell carcinoma.